Over 10,000 results
8-K
EX-99.1
MRK
Merck & Co Inc
25 Apr 24
Merck Announces First-Quarter 2024 Financial Results
6:41am
investigational, multi-valent HPV vaccine designed to provide broader protection against certain cancers and diseases caused by additional HPV types … Exhibit 99.1
News Release
Merck Announces First-Quarter 2024 Financial Results
Sales Reflect Continued Strong Growth in Oncology and Vaccines
6-K
EX-99.1
PRTC
PureTech Health Plc
25 Apr 24
Current report (foreign)
6:30am
myelodysplastic syndromes, and metastatic/locally advanced solid tumors, including head and neck cancers.
LYT-200 has demonstrated a favorable safety … cancers.
In the 2024 post-period, the FDA granted LYT-200 Orphan Drug designation for the treatment of AML as well as Fast Track designation
6-K
AZN
Astrazeneca plc
25 Apr 24
1ST Quarter Results
6:26am
announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies … plus Faslodex in unresectable or recurrent PIK3CA-, AKT1-, or PTEN-altered HR-positive, HER2-negative breast cancer (CAPItello-291).
‒ Datopotamab
424B3
0t86erv3m91 jt
24 Apr 24
Prospectus supplement
5:14pm
424B3
x9hibn 9k4msmjh1w6k
24 Apr 24
Prospectus supplement
5:11pm
DEF 14A
23eqge pdq7
24 Apr 24
Definitive proxy
5:01pm
6-K
EX-99.1
00gow1urfxv
24 Apr 24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4:30pm
6-K
EX-99.1
gij8j
24 Apr 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4:20pm
6-K
EX-99.1
wtj5n
24 Apr 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4:15pm